Echo IQ Ltd (ASX: EIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Echo IQ Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $135.36 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 588.52 million
Earnings per share -0.011
Dividend per share N/A
Year To Date Return 35.29%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Echo IQ Ltd (ASX: EIQ)
    Latest News

    A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
    Share Gainers

    Guess which ASX biotech stock just rocketed 25% on big US news

    Here are all the details.

    Read more »

    EIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Echo IQ Ltd

    EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. It develops and patents algorithm dealing in Prescriptive Analytics. The company was founded by Richard Charles Anstey on March 31, 2010 and is headquartered in Sydney, Australia.

    EIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    31 Dec 2024 $0.23 $-0.01 -4.21% 975,340 $0.24 $0.25 $0.23
    30 Dec 2024 $0.24 $0.01 4.35% 305,929 $0.23 $0.24 $0.23
    27 Dec 2024 $0.23 $-0.01 -4.17% 1,550,233 $0.24 $0.24 $0.23
    24 Dec 2024 $0.24 $0.01 4.26% 875,935 $0.24 $0.25 $0.24
    23 Dec 2024 $0.24 $-0.03 -11.32% 386,145 $0.26 $0.26 $0.24
    20 Dec 2024 $0.27 $0.05 22.73% 1,481,717 $0.23 $0.27 $0.22
    19 Dec 2024 $0.22 $-0.01 -4.35% 1,768,383 $0.23 $0.23 $0.22
    18 Dec 2024 $0.23 $0.01 4.44% 873,373 $0.23 $0.24 $0.23
    17 Dec 2024 $0.23 $0.00 0.00% 951,556 $0.23 $0.23 $0.23
    16 Dec 2024 $0.23 $-0.02 -8.16% 2,874,366 $0.24 $0.24 $0.22
    13 Dec 2024 $0.25 $-0.01 -3.96% 1,093,164 $0.25 $0.25 $0.24
    12 Dec 2024 $0.25 $0.00 0.00% 275,728 $0.25 $0.26 $0.25
    11 Dec 2024 $0.25 $0.01 4.08% 1,522,212 $0.25 $0.25 $0.24
    10 Dec 2024 $0.25 $-0.03 -11.11% 2,349,974 $0.27 $0.27 $0.25
    09 Dec 2024 $0.27 $0.01 3.85% 7,275,816 $0.28 $0.29 $0.27
    06 Dec 2024 $0.26 $0.01 3.92% 1,169,650 $0.26 $0.26 $0.25
    05 Dec 2024 $0.26 $0.00 0.00% 1,180,468 $0.26 $0.26 $0.25
    04 Dec 2024 $0.26 $-0.01 -3.77% 813,425 $0.26 $0.27 $0.25
    03 Dec 2024 $0.27 $0.01 3.92% 511,144 $0.26 $0.27 $0.25

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 Dec 2024 Steven Formica Expiry 8,800,000 $1,980,000
    Options expired.
    17 Dec 2024 Andrew Grover Expiry 11,800,000 $2,655,000
    Options expired.
    29 Oct 2024 Stephen (Steve) Picton Expiry 2,000,000 $450,000
    Options expired.
    28 Jun 2024 Simon Tolhurst Buy 7,100,000 $3
    Off-market trade.
    31 May 2024 Andrew Grover Buy 5,000,000 $250,000
    Exercise of options.
    31 May 2024 Andrew Grover Sell 5,000,000 $700,000
    Off-market trade.
    31 May 2024 Andrew Grover Exercise 5,000,000 $250,000
    Exercise of options.
    31 May 2024 Steven Formica Exercise 5,000,000 $250,000
    Exercise of options. https://www.aspecthuntley.com.au/asxdata/20240607/pdf/02815462.pdf
    31 May 2024 Steven Formica Buy 5,000,000 $250,000
    Exercise of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Stephen (Steve) Picton Non-Executive Director Oct 2021
    Mr Picton has over 35 years of experience in the technology industry having held senior positions in British Telecom (BT) and AAPT prior to him forming gotalk and relaunching LBNCo.
    Mr Steven Allen Formica Non-Executive Director Jul 2018
    Mr Formica brings to the Group practical management and business development experience. He has been a businessman and operations manager for over 31 years in several privately held business ventures including manufacturing, construction, landscape contracting, property development and integrated wholesale and retail businesses.
    Mr Andrew Grover Executive ChairmanExecutive DirectorInterim CEO May 2019
    Mr Grover has 26 years of experience in management, business development, sales & marketing, administration and technology across a diverse range of industries. As a founder and investor in numerous innovative companies, Andrew's businesses have been featured in BRW Fast 100 and Deloitte's Fast 50 over several years.
    Mr Ken Nelson Non-Executive Director Dec 2024
    Mr Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics.
    Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership
    with Medtech Innovator (www.medtechinnovator.org), the largest medical technology and digital
    health startup accelerator globally. In addition to this, Mr Nelson serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam (NASDAQ: BEAT), Acarix (NASDAQ: ACARIX),
    US-based company Epitel, and European-based platform Happitech. Mr Nelson also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and
    the Heart & Brain Accelerator of the American Heart Association.
    Ms Jessamyn Sarah Lyons Company Secretary Oct 2021
    -
    Deon Strydom Chief Commercial Officer
    -
    Prof. David Playford Chief Medical Advisor
    -
    Philip Woolff Chief Operating Officer
    -
    Prof. Geoff Strange Chief Research & Strategy Officer
    -
    Sean Bryceland Chief Technology Officer
    -
    Jessamyn Sarah Lyons Company Secretary
    -
    Dane Brescacin VP Regulatory Affairs
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 33,199,295 5.64%
    A22 Pty Ltd 28,500,000 4.84%
    Stevsand Investments Pty Ltd <Steven Formica Family A/C> 27,100,000 4.60%
    Richmond Bridge Superannuation Pty Ltd <Richmond Bridge Super A/C> 21,764,854 3.70%
    Alerte Digital Health Pte Ltd 17,373,863 2.95%
    Bellcoo Investments Pty Ltd < The Northlake S/F A/C> 15,248,099 2.59%
    Mr Brian Joseph Glynn 13,875,483 2.36%
    King Corporate Pty Ltd 13,283,334 2.26%
    Shah Nominees Pty Ltd <Louis Carsten Super Fund A/C> 12,700,000 2.16%
    Heath Nominees (Aust) Pty Ltd < The Heath Family A/C> 12,361,373 2.10%
    Shah Nominees Pty Ltd 10,060,162 1.71%
    BNP Paribas Noms Pty Ltd <Global Markets> 9,952,397 1.69%
    Hunt Prosperity Pty Ltd <Investius Pb Micro Cap A/C> 9,803,001 1.67%
    Belgravia Strategic Equities Pty Ltd 8,526,000 1.45%
    Ms Laura Bailey 8,250,000 1.40%
    T Mitchell Pty Ltd < The T Mitchell S/F A/C> 7,668,236 1.30%
    Shriver Nominees Pty Ltd 7,150,000 1.21%
    Kli Pty Ltd <The T Teh'S Family A/C> 6,840,000 1.16%
    Xeryus International Pty Ltd 6,590,481 1.12%
    Mikado Corporation Pty Ltd <Jfc Superannuation A/C> 6,300,000 1.07%

    Profile

    since

    Note